138 results about "Bronchitis copd" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention provides a method of delivering, by intermittent inhalation, 200 ppm to 320 ppm gNO for 10 to 45 minutes 2 to 5 times per day to provide a therapeutic amount of gaseous nitric oxide (gNO) wherein the therapeutic amount is a nitric oxide-load (NO load) of 300 ppm-hrs to 900 ppm-hrs of gNO per day over a period of at least 14 days to a patient in need thereof, wherein the patient has a condition associated with a pathogenic microorganism, wherein the intermittent inhalation comprises inhalation of the gNO for a first time period, followed by inhalation of a gas essentially devoid of gNO for a second time period.

The utility model provides an atomizing mask. The atomization cover comprises a cover body, a medicine inlet pipe and a breathing hole, the cover body is worn on the face of the human body, the medicine inlet pipe is connected to the cover body, and the breathing hole is formed in the cover body. The shielding assembly comprises a shielding plate and a plurality of mounting parts, the mounting parts are detachably mounted on the medicine inlet pipe, and the shielding plate is mounted on the mounting parts, shields the mouth of the human body and is configured to abut against the mouth of the human body under the action of the mounting parts. The utility model further provides an atomizer which comprises an atomizing mask and an atomizer body, and the atomizer body is detachably installed at the end, away from the shielding plate, of the medicine inlet pipe. According to the atomization mask, when rhinitis, nasosinusitis, bronchitis, pneumonia and other diseases are treated, liquid medicine is prevented from flowing back into the oral cavity of a user, it is guaranteed that the atomized liquid medicine is sucked into the airway of a patient as much as possible, the treatment effect of the device is improved, and the treatment effect is improved. The liquid medicine can be prevented from entering the oral cavity, so that the use comfort of a user is reduced, and bacterial infection is avoided.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides a construction method and an expression system of recombinant protein for preventing infectious bronchitis of chicken and application of the recombinant protein. Coding DNA of multi-antigen epitope tandem protein from infectious bronchitis virus N, S1 protein is connected to obtain a fusion recombinant protein IBV: NS1 coding gene, a recombinant expression plasmid pET28a-IBV: NS1 is constructed and transferred into E. coli Rosetta (DE3) competent cells to obtain an E. coli genetic engineering expression bacterium Ec-RD-pET28a-IBV: NS1, and the fusion recombinant protein IBV: NS1 is obtained through induced expression and massive purification. And mixing with an immunologic adjuvant to prepare the subunit vaccine. The subunit vaccine has the advantages of high antigen expression quantity, long antibody maintenance time, high purity, good safety, strong immunogenicity and strong protectiveness, and can effectively prevent infectious bronchitis.

The invention discloses a primer pair and a fluorescent probe for detecting an infectious bronchitis virus as well as application and a detection method of the primer pair and the fluorescent probe, and relates to the technical field of biological virus detection. Wherein the nucleotide sequence of a forward primer in the primer pair is as shown in SEQ ID No.1, the nucleotide sequence of a reverse primer is as shown in SEQ ID No.2, and the nucleotide sequence of the fluorescent probe is as shown in SEQ ID No.3; the 5'end of the fluorescent probe is modified by FAM, and the 3 'end of the fluorescent probe is modified by TAMRA. By implementing the kit, IBV of various genotypes can be accurately detected, and a good basis is provided for early diagnosis of IBV.

The invention discloses a primer for detecting and distinguishing genotypes of avian infectious bronchitis viruses and application, and belongs to the technical field of biological detection. The primer combination comprises a universal primer and a probe group I for detecting an IBV total group, a specific primer and a probe combination II for detecting a GI-19 genotype, and a specific primer and a probe combination III for detecting a GVI-1 genotype, and nucleotide sequences are respectively shown as SEQ ID NO.1-9; different fluorophores are respectively marked at 5'ends of each group of probes, and corresponding quenching groups are marked at 3 'ends of each group of probes. The primer combination provided by the invention has high specificity and high sensitivity, rapid detection of the IBV and accurate distinguishing of main epidemic genotypes (GVI-1 and GI-19) can be completed in a single reaction, complex sequencing and analysis steps in a traditional method are omitted, the detection efficiency is greatly improved, and the primer combination has a good application prospect. And a convenient tool is provided for farm epidemic situation monitoring and clinical diagnosis.

The present invention discloses a traditional Chinese medicine composition for treating chronic bronchitis combined with emphysema. The composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rehmannia, 18-22 parts of schisandra, 15-25 parts of pinellia, and 20-30 parts of poria. The composition nourishes the liver, spleen, and kidneys, reduces stomach qi, purges the lungs, and relieves asthma, promotes diuresis and reduces swelling, promotes blood circulation and removes blood stasis, regulates qi and resolves phlegm, and is suitable for treating chronic bronchitis combined with emphysema. The present invention also discloses a preparation method and use thereof.

To provide interventional procedures which are easy to control, match pathophysiologic aberrancies, allow treatment of large surface areas at appropriate depths, and can limit amounts of inflammatory response and remodeling.SOLUTION: Systems and methods are provided for treating pulmonary tissues via delivery of energy to target tissue using a pulmonary tissue modification system (100) such as an energy delivery catheter (102) system. Example pulmonary tissues include the epithelium (goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, and / or nerves. The system may be used to treat a variety of pulmonary diseases or pulmonary disorders such as COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), and / or acute bronchitis.SELECTED DRAWING: Figure 5

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

This invention discloses the application of Akkermansia in the preparation of drugs for the prevention and treatment of avian infectious bronchitis virus (AIB). Through research, this invention has found that Akkermansia can improve the survival rate of chickens infected with AIB and inhibit the replication of AIB. This demonstrates that Akkermansia has important applications in the preparation of drugs for the prevention and / or treatment of AIB infection, providing a new solution for the treatment of AIB infection, and can be specifically applied in drugs or feed additives for combating AIB infection.

This invention discloses a traditional Chinese medicine composition for preventing and treating inflammatory diseases in animals, its preparation method, and its application, belonging to the field of traditional Chinese medicine composition technology. The raw materials of this traditional Chinese medicine composition for preventing and treating inflammatory diseases in animals, by mass percentage, include 8%-12% extract of honeysuckle branches and leaves, 8%-12% extract of dipsacus root, 8%-12% chrysanthemum, 4%-6% mulberry leaves, 4%-6% licorice root, 0.8%-1.2% peppermint, and 50.8%-67.2% anhydrous glucose. It has good anti-inflammatory effects and can effectively alleviate inflammatory responses caused by LPS. In particular, it has good therapeutic and ameliorative effects on the clinically prevalent porcine reproductive and respiratory syndrome (PRRS) and infectious bronchitis in chickens, effectively reducing morbidity and mortality, and improving production performance.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

The invention relates to an infectious bronchitis subunit vaccine based on a nano-skeleton technology. Specifically, the invention provides a fusion protein which sequentially comprises an infectious bronchitis virus S protein fragment or a mutant thereof, a connecting peptide and helicobacter pylori ferritin from an N terminal to a C terminal, wherein the infectious bronchitis virus S protein fragment is S1 protein, and the amino acid sequence of the S protein fragment is as shown in SEQ ID NO. 2; the mutant of the chicken infectious bronchitis virus S protein fragment is S1-2 protein or S1-3 protein, the amino acid sequence of the S1-2 protein is shown as SEQ ID NO.4, and the amino acid sequence of the S1-3 protein is shown as SEQ ID NO.5. The invention further discloses a preparation method of the chicken infectious bronchitis virus S protein fragment.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The invention discloses application of a metabolite of arachidonic acid in mycoplasma pneumonia, and relates to the technical field of biological detection. According to the application of the arachidonic acid metabolite in mycoplasma pneumonia, the arachidonic acid metabolite is detected, so that the content of the arachidonic acid metabolite in a biological sample is accurately detected through chromatography-mass spectrometry according to the change of the level of the metabolite in inflammatory reaction, and the arachidonic acid metabolite can be used as an auxiliary index for diagnosis of inflammatory diseases such as pneumonia; if in a pneumonia patient, the concentration may be higher than that of a healthy person; in different types of inflammatory diseases, metabolite change modes of arachidonic acid are different, and detection of the metabolite in combination with other clinical indexes is helpful for distinguishing pneumonia and other inflammatory diseases with similar symptoms, such as differential diagnosis of bronchitis and the like; meanwhile, in the pneumonia development process, the inflammation progress can be known by detecting the content of metabolites.

1. The name of the design product: water negative ion device. 2. The use of the design product: for air purification and disinfection, auxiliary treatment of chronic bronchitis and non-acute insomnia. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention provides a QX type avian infectious bronchitis virus mRNA vaccine and application thereof. The gene sequence of the mRNA vaccine molecule is shown as SEQ ID NO.9 or SEQ ID NO.13. The invention also provides a preparation method of the QX type avian infectious bronchitis virus mRNA vaccine. The preparation method of the QX-type avian infectious bronchitis virus mRNA vaccine molecule provided by the invention is simple to operate, preparation can be performed only by knowing a gene sequence, and compared with an inactivated vaccine, the production price is low, and the dosage is small; compared with attenuated live vaccines, the vaccine is short in production period and safe.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

A novel infectious bronchitis virus (IBV) serotype, to isolated attenuated IBV strains derived therefrom, and to live or inactivated vaccines against infectious bronchitis made using the isolated attenuated IBV strain.

The invention relates to a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination and a kit for an infectious bronchitis virus. The invention belongs to the field of biology, and discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) primer probe combination for GI-13 / GI-19 / GVI-1 typing and general detection of an infectious bronchitis virus. Comprising a first primer probe combination for distinguishing an infectious bronchitis virus from other viruses, a second primer probe combination for identifying a GI-13 type infectious bronchitis virus, and a third primer probe combination for identifying a GI-19 type infectious bronchitis virus, and the fourth primer probe combination is used for identifying the GVI-1 type avian infectious bronchitis virus. The PCR primer probe combination is suitable for an RT-qPCR detection system, and can be used for effectively distinguishing GI-19, GI-13 and GVI-1 type IBV viruses; meanwhile, the invention further discloses a kit.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

The invention provides an application of children Danqing Shuanglian granules in preparation of drugs for treating acute inflammation. The acute inflammation comprises acute upper respiratory tract infection, bronchitis, amygdalitis and pneumonia caused by virus infection (H1N1, H3N2, FluB and HRSV) or abnormal immunoreaction. Raw materials of the granules comprise nauclea officinalis, artemisia apiacea, scutellaria baicalensis and other traditional Chinese medicinal materials and anti-inflammatory regulatory peptide. The preparation process comprises the following steps: extracting volatile oil by steam distillation, extracting effective components by combining microwave assistance and ultrasonic enhancement, carrying out beta-cyclodextrin inclusion on polypeptide to enhance the stability, and finally granulating to obtain granules with the water content of less than or equal to 6%. Experiments show that the inhibition rate of the drug to HRSV under the maximum non-toxic concentration reaches 81.8% + / -2.0%, and the therapeutic index is SIgt; 2, the latency period of ammonia water induced mouse cough can be remarkably prolonged, the cough frequency is reduced, the antiviral, anti-inflammatory and antitussive effects are achieved, and a safe and effective traditional Chinese medicine choice is provided for clinical treatment of viral acute inflammation.

The invention discloses colloidal gold immunochromatography test paper for rapidly detecting pigeon I-type paramyxovirus and a preparation method of the colloidal gold immunochromatography test paper. Viral diseases of pigeons, especially pigeon plague virus and pigeon adenovirus, are rapidly detected on the basis of a newly developed test strip, and the operation is simple and convenient; according to the design of antigens and antibodies of the pigeon plague virus and the pigeon adenovirus, rapid detection of the pigeon plague virus and the pigeon adenovirus can be conveniently carried out, and the obtained test strip is high in specificity and high in sensitivity. The pigeon I-type paramyxovirus detection kit has the advantages that the pigeon I-type paramyxovirus detection kit does not have cross reaction with chicken infectious bronchitis, chicken egg drop syndrome, chicken Marek's disease, avian influenza, fowl adenovirus, infectious bursal disease, escherichia coli, salmonella and other samples, but can have cross reaction with Newcastle disease, so that the pigeon I-type paramyxovirus detection kit can be used for diagnosing pigeon I-type paramyxovirus and Newcastle disease.

The invention discloses a Tibetan medicine Banjiaojiaopian pellet preparation, which comprises raw materials and auxiliary materials, the raw materials comprise the following components: gentiana algida, agilawood, choerospondias axillaris, white sandalwood, myristica fragrans, tabasheer, alpine horseradish, costus root, fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit, tinospora sinensis merr, corydalis impatiens, clove and liquorice, and the auxiliary materials comprise an adhesive and a filler microcrystalline cellulose; the technological parameters for preparing the pellet preparation by adopting centrifugal granulation are as follows: the liquid spraying speed is 50ml / min, the number of revolutions of a turntable is 30r / min, and the air inlet temperature is 75 DEG C. Compared with traditional pills, the pellet preparation provided by the invention has the advantages of high dissolution rate, obviously improved bioavailability, reliable drug effect, accurate taking dosage, stable quality, low cost, good treatment effect, fine production process, good reproducibility, good quality controllability, high industrial production efficiency and wide application range.

The invention provides a polyethylene glycol (PEG) modified glucocorticoid medicine and application thereof, and relates to the technical field of medicinal chemistry, and the medicine comprises but is not limited to asthma, chronic obstructive pulmonary diseases, bronchitis, rhinitis and the like. The invention relates to a polyethylene glycol modified glucocorticoid drug. The polyethylene glycol modified glucocorticoid drug comprises but is not limited to the following compounds: KYAC-03, KYAC-04, KYAC-08, KYAC-09, KYAC-10, KYAC-11, KYAC-14, KYAC-16, KYAC-17, KYAC-20, KYAC-33 and KYAC-39. An anti-asthma and allergic rhinitis pharmacological experiment shows that the PEG-modified glucocorticoid medicine provided by the invention can remarkably improve disease symptoms and signs of asthma model mice and allergic rhinitis model mice, and remarkably reduces the administration dosage of glucocorticoid, so that the side effects of the whole body are reduced.

The invention relates to a preparation method and application of a traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm, the preparation is prepared from eight medicinal materials including honey ephedra, bitter apricot kernel reformed, aster tataricus and the like through a staged extraction-multi-stage refining-composite stabilization integration process, volatile oil components are subjected to exclusive distillation concentration, non-volatile components are subjected to ethanol-water two-phase extraction, and then the volatile oil components are subjected to ethanol-water two-phase extraction to obtain the traditional Chinese medicine atomization inhalant for diffusing the lung and reducing phlegm. Chitosan flocculation is coupled with precise ultrafiltration to realize deep purification; molecular-level stabilization fusion of volatile oil and a refined water phase is innovatively realized through a composite surfactant system, and finally, a high-stability sterile solution meeting the requirement of an inhalant is prepared. The process overcomes the common problems that a compound traditional Chinese medicine atomized preparation is poor in clarity, effective components are easy to degrade and the atomization performance is poor, and it is ensured that the active components can be efficiently converted into lung targeted deposition superfine aerosol. The product is suitable for respiratory system diseases such as acute bronchitis, asthma turbid phlegm obstructing lung syndrome and the like, and has the advantages of quick response, high local drug concentration and good safety.